# A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct07021976` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07021976](<https://clinicaltrials.gov/study/NCT07021976>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07021976

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 228 participants.

## Technical summary

Registry record NCT07021976. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-11 (actual); primary completion 2026-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 228 participants (enrolled count; ClinicalTrials.gov record NCT07021976, source copy `cardio:ctgov-nct07021976-2026-08-24`, retrieved 2026-10-31)
- Started: 2025-08-11 (actual) (ClinicalTrials.gov record NCT07021976, source copy `cardio:ctgov-nct07021976-2026-08-24`, retrieved 2026-10-31)
- Primary completion: 2026-09 (anticipated) (ClinicalTrials.gov record NCT07021976, source copy `cardio:ctgov-nct07021976-2026-08-24`, retrieved 2026-10-31)
- Completion: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07021976, source copy `cardio:ctgov-nct07021976-2026-08-24`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07021976, source copy `cardio:ctgov-nct07021976-2026-08-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07021976-2026-08-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
- Condition: Obstructive Hypertrophic Cardiomyopathy
- Intervention (Drug): HRS-1893 Tablets
- Intervention (Drug): HRS-1893 Placebo Tablets
- Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Shandong Suncadia Medicine Co., Ltd. (`cardio:org-shandong-suncadia-medicine-co-ltd`)

## Provenance

Content hash: 432416e0e32ee1e2ab90dfc04e09de0c3e28024f31fa8de10dba609108b6c7c2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
